Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,473 across all filing types
Latest filing 2020-12-04 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASC22 (ENVAFOLIMAB) IS SAFE AND WELL TOLERATED IN PHASE IIa HBV STUDY AND PHASE IIb HBV CLINICAL TRIAL HAS BEEN INITIATED
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding clinical trial results and the initiation of a new phase IIb clinical trial for a drug candidate. It is short (2016 characters) and does not contain financial data, detailed financial statements, or comprehensive report content. It is not an annual or interim report, earnings release, or any detailed financial or governance report. The document is an announcement of clinical trial progress and safety data, which does not fit into categories like financial reports or management reports. It is also not a regulatory filing related to compliance or certifications. Given the nature and length, and that it is an announcement rather than a full report, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2020-12-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/11/2020. It is addressed to the Hong Kong Exchanges and Clearing Limited, indicating it is a regulatory filing related to share capital changes. The content focuses on share capital movements, share options, and confirmations related to securities issuance, without financial statements or earnings data. This type of document is a regulatory announcement about share capital and securities movements rather than a full financial report or earnings release. It fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2020-12-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on shares issued, repurchased, and related confirmations in compliance with the Listing Rules of the Hong Kong Stock Exchange. The content focuses on share capital changes and repurchase activities rather than financial results or management commentary. This matches the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length (9151 characters) and detailed transactional data support this classification rather than a brief announcement or a regulatory filing fallback.
2020-12-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 November 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share capital changes. The content is focused on share capital changes and movements during a specific month, which aligns with disclosures about share issues, repurchases, and capital structure changes. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is not a report but a regulatory filing about share capital movements. This fits best under the category 'Share Issue/Capital Change' (SHA). The document length is substantial and contains detailed data, confirming it is not a mere announcement or certification. Therefore, the classification is SHA with high confidence.
2020-12-01 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a disclosure return related to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed information on share issues, repurchases, and confirmations of compliance with listing rules. The content focuses on reporting share capital changes and repurchase activities rather than presenting financial results, management commentary, or regulatory certifications. The document length is 8627 characters, which is substantial and contains detailed transactional data. This matches the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. There is no indication that this is an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the appropriate classification is POS.
2020-11-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed information on share issues, repurchases, cancellations, and confirmations related to compliance with listing rules on the Hong Kong Stock Exchange. The content focuses on reporting changes in share capital and share repurchases, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document length is 8604 characters, which is substantial but the content is clearly a regulatory disclosure about share capital changes and repurchases. This fits the definition of 'Transaction in Own Shares' (POS) as it reports on the company's repurchase of its own shares and changes in issued share capital.
2020-11-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.